Immunologic

针对 原发性免疫缺陷 的干细胞疗法:成本、证据和如何选择诊所

Primary immunodeficiency diseases encompass a heterogeneous group of inherited disorders affecting humoral immunity (B cells, antibody production), cellular immunity (T cells), complement, phagocytes, and innate immunity.

原发性免疫缺陷的干细胞疗法如何研究

Primary immunodeficiency diseases encompass a heterogeneous group of inherited disorders affecting humoral immunity (B cells, antibody production), cellular immunity (T cells), complement, phagocytes, and innate immunity. Stem-cell research investigates whether fetal stem cells and placental mesenchymal stem cells can regenerate lymphoid tissue, promote T-cell and B-cell development within thymic or splenic niches, enhance phagocytic function, and restore immunological tolerance. With 91 registered trials and 13 currently recruiting, the biological rationale targets immune reconstitution through direct progenitor support and paracrine enhancement of developmental microenvironments. Early clinical data suggest potential for improving T-cell counts and function, enhancing antibody responses, reducing infection burden, and improving outcomes in severe combined immunodeficiency and other forms.

原发性免疫缺陷: 干细胞疗法概览 (2026)
指示性成本 · 保加利亚 (EU)€3,000–€8,000
全球市场成本范围€19,000–€24,000 (bookinghealth.com)
研究的主要细胞类型Fetal Stem Cells, MSCs from Amniotic Membrane
批准状态批准(仅限血液/免疫)
注册的临床试验 (ClinicalTrials.gov)91 · 13 recruiting now

For the clinic's own description, see how Stem Plus describes its Primary Immunodeficiency programme ↗.

批准状态 — 批准(仅限血液/免疫): Haematopoietic (blood/immune) stem-cell transplantation is an established, approved treatment for selected blood and immune disorders; other cell protocols are investigational.

证据对原发性免疫缺陷的显示

Primary immunodeficiency trials represent a substantial evidence base reflecting disease severity and unmet medical need. Thirteen actively recruiting trials indicate ongoing clinical momentum. Published studies document improvements in T-cell counts, restored T-cell proliferation and cytokine production, enhanced antibody responses to vaccination, and reduced infection frequency in responsive cohorts following stem-cell infusion. Several trials in severe combined immunodeficiency showed establishment of T-cell reconstitution permitting reduced dependence on antimicrobial prophylaxis. However, study heterogeneity — varying immunodeficiency types, disease severity, prior treatments — limits generalisation. Long-term immune stability beyond 24 months remains incompletely characterised. Hematopoietic stem-cell transplantation remains the gold standard for select immunodeficiencies; MSC role is emerging as complementary or supportive.

Clinical-trial reality check (Jun 2026, ClinicalTrials.gov): 91 registered stem-cell trials for Primary Immunodeficiency (13 recruiting now). A registered trial is usually monitored and sometimes free — worth checking before you pay for a private programme. Browse trials ↗

用于原发性免疫缺陷的细胞类型

Depending on assessment, a Primary Immunodeficiency protocol may draw on:

原发性免疫缺陷程序的成本

Primary immunodeficiency stem-cell treatment costs typically range €4,000–8,000 per infusion, reflecting the complexity of immunological assessment and monitoring. Fetal stem cells, when used, incur higher sourcing and manufacturing costs than placental MSCs, potentially exceeding €8,000 per cycle. Repeat infusions are common; multi-cycle protocols may total €15,000–25,000. Extensive immunological testing — T-cell subset enumeration, T-cell proliferation assays, antibody titers, vaccine responses — adds €1,500–3,000 to each cycle. Hospital-based immunology programmes typically charge €4,500–7,000; private boutique immune-therapy centres may exceed €8,000. European centres (Germany, Spain, Italy, Austria) generally offer more structured pricing than boutique clinics.

Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Primary Immunodeficiency cost-by-country breakdown, or compare the best countries for Primary Immunodeficiency →

在权衡原发性免疫缺陷的所有选项吗? See the full Primary Immunodeficiency treatment-options comparison — standard care, alternatives and where stem-cell therapy fits, side by side.

Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Primary Immunodeficiency.

人们对原发性免疫缺陷提出的问题

完整原发性免疫缺陷常见问题 → · 原发性免疫缺陷成本分解 →

来源和进一步阅读

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

Useful tools & guides: 我是候选人吗? · 哪种细胞类型? · Types of clinics & best countries · 成本计算器

由 StemCellAtlas 的编辑团队进行医学审查,与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus(索菲亚)的,根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.

欧洲品质的细胞疗法,没有欧洲的价格。

位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起,仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。

免费医疗评估